Return to homepagePandemic Pact

Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2)

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 202002OV3

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2022

  • Known Financial Commitments (USD)

    $750,000

  • Funder

    Canadian Institutes of Health Research (CIHR)

  • Principal Investigator

    N/A

  • Research Location

    China

  • Lead Research Institution

    Unity Health Toronto

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

SARS-CoV-2, cell and animal models, a candidate drug, biotech company, and patients (in China)]. This research proposal focuses on the role of angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor to enter human body. We propose to do basic studies to examine the specific mechanisms involved, as well as to perform a clinical trial in COVID-19 patients in China using recombinant human ACE2 (rhACE2).